Webinar
Nov 21, 2019

Dr. Nicholas van As - Royal Marsden Hospital, London
November 21st - 5:00pm CET, 9:00am PST

Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): Acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial

Dr Nicholas van As is the Medical Director of the Royal Marsden Hospital, Consultant Clinical Oncologist in the Urology Unit, and a Reader at the Institute of Cancer Research.

Dr van As is a clinical lead for stereotactic body radiotherapy (SBRT) at The Royal Marsden, national clinical lead for NHS England's evaluation program for SBRT. He is Chair of the UK SBRT Consortium. He leads a number of clinical trials, most notably he is chief investigator for the international clinical trial PACE, comparing SBRT to image-guided radiotherapy and surgery for treating localized prostate cancer.

Dr van As' main research interests are in stereotactic and image-guided radiotherapy, treatment of oligometastatic disease, risk prediction in early prostate cancer, and functional magnetic resonance imaging. He has published numerous papers on these subjects and delivered presentations at international meetings.

Dr. Collins  Moderated by: Sean Collins, MD, PhD - MedStar Georgetown University Hospital, DC.
Dr. Collins is the director of the 
CyberKnife Prostate Program at MedStar Georgetown University Hospital and associate professor of Radiation Medicine at Georgetown University School of Medicine. Dr. Collins joined Georgetown in 2006 after completing his residency in radiation oncology at MedStar Georgetown and the Lombardi Comprehensive Cancer Center and, previously, a surgical internship at the Hospital. In addition to his medical degree, he also holds a doctorate in Biological Chemistry, both from the University of Michigan's Medical Scientist Training Program.

CyberKnife Prostate
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): Acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial: RECORDED PRESENTATION
Dr. Nicholas van As | Royal Marsden Hospital, London
CyberKnife Prostate
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): Acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial: RECORDED Q&A SESSION
Dr. Nicholas van As | Royal Marsden Hospital, London